

ASX ANNOUNCEMENT

CELLMID APPOINTS DENNIS ECK NON-EXECUTIVE DIRECTOR

SYDNEY, Monday, 26 March 2018: Cellmid Limited (ASX: CDY) (the **Company**), is pleased to advise that it has appointed Mr Dennis Eck to the Board as non-executive director.

Mr Eck, now a professional investor, has 40 years' senior management experience in the retail sector leading the strategic direction of companies such as American Stores, Vons and ULTA in the United States and Coles Myer in Australia.

His retail experience spans from fashion through groceries and includes cosmetics and hair salons. As a senior strategist, Mr Eck has helped reshape the operations of several retail businesses delivering outstanding shareholder returns.

"We are delighted to welcome Dennis to the board and looking forward to his continued valuable input regarding our product and distribution strategy for évolis®" said Chairman of the Board, Dr David King.

"I have been following the Company's progress since early 2017 and have been impressed by the development of the drug portfolio as well as the positioning and distribution strategy of the évolis® products. With the substantial US and Asian market opportunities for évolis®, I'm looking forward to contribute as a non-executive director and assist in delivering shareholder value" said Dennis Eck.

In December 2017 Mr Eck made a strategic investment in Cellmid through a private placement acquiring 2,700,000 fully paid ordinary shares. His experience and strategic insights will be important to guide the Company's market development.

In addition to his businesses and investment interests Mr Eck is a significant donor to charitable and not-for-profit organisations.

End

Contact:
Maria Halasz, CEO
T +612 9221 6830

 @mariahalasz

Investor Relations
Rebecca Wilson
+61 417 382 391

rwilson@we-buchan.com

Media
Gabriela Czwarnos

gczwarnos@we-buchan.com

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Advangen Limited and hair growth products

Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of anti-aging hair care products. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia and Japan with a USA launch currently ongoing. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.